Evidence map›Paper›PMID 30536645›Full record

ArticleBiotechnology and bioengineering2019

Amber suppression coupled with inducible surface display identifies cells with high recombinant protein productivity.

Lina Chakrabarti, Li Zhuang, Gargi Roy, Michael A Bowen, William F Dall'Acqua, Pam Hawley-Nelson, Marcello Marelli

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lina ChakrabartiCell Culture and Fermentation Science, MedImmune, Gaithersburg, Maryland.
Li ZhuangAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland.
Gargi RoyAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland.
Michael A BowenAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland.
William F Dall'AcquaAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland.
Pam Hawley-NelsonCell Culture and Fermentation Science, MedImmune, Gaithersburg, Maryland.
Marcello MarelliAntibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland.ORCID 0000-0001-7095-8263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell line development (CLD) for biotherapeutics is a time- and resource-intensive process requiring the isolation and screening of large numbers of clones to identify high producers. Novel methods aimed at enhancing cell line screening efficiency using markers predictive of productivity early in the CLD process are needed to reliably generate high-yielding cell lines. To enable efficient and selective isolation of antibody expressing Chinese hamster ovary cells by fluorescence-activated cell sorting, we developed a strategy for the expression of antibodies containing a switchable membrane-associated domain to anchor an antibody to the membrane of the expressing cell. The switchable nature of the membrane domain is governed by the function of an orthogonal aminoacyl transfer RNA synthetase/tRNApyl pair, which directs a nonnatural amino acid (nnAA) to an amber codon encoded between the antibody and the membrane anchor. The process is "switchable" in response to nnAA in the medium, enabling a rapid transition between the surface display and secretion. We demonstrate that the level of cell surface display correlates with productivity and provides a method for enriching phenotypically stable high-producer cells. The strategy provides a means for selecting high-producing cells with potential applications to multiple biotherapeutic protein formats.

Indexed as

Codon, TerminatorAnimalsBatch Cell Culture TechniquesCHO CellsCricetulusGenetic VectorsHumansImmunoglobulin GRecombinant ProteinsTransfectionCodon, TerminatorImmunoglobulin GRecombinant Proteinsamber suppressioncell line developmentenrichmentsurface displayunnatural amino acids

Identifiers

PMID30536645
PMCPMC6590230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.